JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
Author:
Affiliation:
1. Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK
Funder
Gilead Sciences, Inc.
AbbVie
Celgene
Bristol-Myers Squibb
Pfizer
Lilly
Galapagos
Janssen
Novartis
UCB
Boehringer-Ingelheim
Publisher
Oxford University Press (OUP)
Subject
Pharmacology (medical),Rheumatology
Link
http://academic.oup.com/rheumatology/article-pdf/58/Supplement_1/i43/27984844/key276.pdf
Reference107 articles.
1. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases;Schwartz;Nat Rev Drug Discov,2017
2. Novel therapies for immune-mediated inflammatory diseases: what can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis?;Baker;Ann Rheum Dis,2018
3. Janus kinase inhibitors in autoimmune diseases;O’Shea;Ann Rheum Dis,2013
4. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects;Banerjee;Drugs,2017
5. Structure and signalling in the IL-17 receptor family;Gaffen;Nat Rev Immunol,2009
Cited by 236 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Design, synthesis and activity screening of cedrol derivatives as small molecule JAK3 inhibitors;Bioorganic Chemistry;2024-11
2. Blockade of rheumatoid arthritis synovial fluid-induced sensory neuron activation by JAK inhibitors;2024-08-19
3. Evaluation of the Efficacy of Tofacitinib, a JAK Inhibitor, in Alleviating Sepsis-Induced Multiple Organ Dysfunction Syndrome;Drug Research;2024-08-12
4. Real-world comparative study of drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis;PLOS ONE;2024-07-11
5. Successful treatment of rheumatoid neutrophilic panniculitis with tofacitinib;Anais Brasileiros de Dermatologia;2024-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3